Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration

Arch Neurol. 1995 Aug;52(8):814-8. doi: 10.1001/archneur.1995.00540320098016.

Abstract

Objective: To report the clinical and immunological response to immunosuppressive treatment with cyclophosphamide in two patients with paraneoplastic cerebellar degeneration.

Design: Case reports. Clinical and immunological follow-up data available for 4 1/2 years in the first patient and for 2 years in the second patient.

Setting: A 1500-bed university hospital and a 1200-bed university teaching hospital.

Intervention: Cyclophosphamide intermittent treatment.

Main outcome measure: Clinical disability.

Results: One of the patients, who was treated from an early stage, recovered completely. The other patient showed a partial clinical response. While the two patients were receiving a maintenance regimen with cyclophosphamide, the conditions of both patients remained stable for at least 2 years. In both patients, intrathecal antibody synthesis declined considerably.

Conclusion: Early induction of immunosuppressive therapy with cyclophosphamide should be tried in treating patients with paraneoplastic cerebellar degeneration.

Publication types

  • Case Reports

MeSH terms

  • Cerebellar Diseases / drug therapy*
  • Cerebellar Diseases / immunology*
  • Cerebellar Diseases / pathology
  • Cyclophosphamide / therapeutic use*
  • Cyclosporine / therapeutic use*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Paraneoplastic Syndromes / drug therapy*
  • Paraneoplastic Syndromes / immunology*
  • Paraneoplastic Syndromes / pathology
  • Purkinje Cells / pathology

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Cyclophosphamide